Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O'Cearbhaill, Anneke Westermann, Domenica Lorusso, Sharad Ghamande, Dearbhaile C. Collins, Susana Banerjee, Cara A. Mathews, Christine Gennigens, David Cibula, Krishnansu S. Tewari, Kristine Madsen, Fatih Köse, Amanda L. Jackson, Ingrid A. Boere, Giovanni Scambia, Leslie M. Randall, Azmat Sadozye, Jean François BaurainEelke Gort, Michal Zikán, Hannelore G. Denys, Nelleke Ottevanger, Frédéric Forget, Camilla Mondrup Andreassen, Lamar Eaton, Michael J. Chisamore, Leonardo Viana Nicacio, Ibrahima Soumaoro, Bradley J. Monk

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences